Financial consideration means value that is given or received either directly or indirectly through sales, barter, trade, fees, charges, dues, contributions or donations.
Financial consideration means value that is given or received
Financial consideration means value that is given or received either directly or indirectly through sales, barter, trade, fees, charges, dues, contributions or donations; but does not include: homegrown marijuana that is given or received when nothing is given or received in return; or homegrown marijuana products that are given or received when nothing is given or received in return.
Examples of Financial consideration in a sentence
Financial consideration for this investment included, the capital construction cost, the City’s annual revenue, operating costs (both cash and non-cash) and a maximum payback period.
Financial consideration from proponents will enable the LRA to meet these obligations.
Financial consideration include royalties on future annual net sales.
Financial consideration for use of Cities owned space should be included as part of Contractor’s price.
Financial consideration alone will not be the sole determining factor in the selection process.
More Definitions of Financial consideration
Financial consideration means value that is given or received directly or indirectly through sales, fees, charges, dues, contributions or donations. "Financial consideration" shall not include:
Financial consideration means the total amount in Euro offered by a Candidate as per his Financial Offer.
Financial consideration means the total amount of money offered by each Eligible Investor in its Financial Offer.
Financial consideration. ' means the total amount of money in euro offered by a Candidate in its Financial Offer or its improved Financial Offer for the purchase of the ownership right on the Property.
Financial consideration means the total amount of money in euro offered by a Candidate in its Financial Offer.
Financial consideration means sublicense issue fees, signing fees and sublicense milestone payments made by Sublicensees to Elixir in consideration of sublicenses under the grants contained in Sections 2.1 and 2.2, but does not include (i) royalties and other payments which are based on the level of sales, (ii) payments made at fair market value for equity or debt securities of Elixir or its Affiliates, or (iii) payments contractually committed to cover the costs of future research, Development or Commercialization of Licensed Compound(s) or Licensed Product(s) by Elixir or its Affiliates, including payments for research and development (including those for FTEs), clinical, protecting or enforcing patent rights, and other administrative and scientific costs.
Financial consideration will mean license fees, signing fees, option fees, milestone payments and any other consideration (including non-monetary consideration) paid to, or otherwise received by, Clovis or any of its Affiliates in consideration for the establishment of a Sublicensee or Distributor relationship (and without reduction for any additional Patents or Know-How or other intellectual property rights granted or commitments made in connection therewith), but does not include (i) revenues from sales of Licensed Products by Clovis to Sublicensees or Distributors; (ii) royalties metered on sales of Licensed Products by Selling Parties, (iii) payments contractually committed to reimburse the Fully Allocated Costs of future Development of the Lead Candidate and Licensed Products, provided that any amounts received in excess of such costs (such as, for example, a profit share) will be treated as “Financial Consideration” hereunder, and (iv) payments received to purchase securities of Clovis at fair market value, provided that any premium paid over fair market value will be treated as “Financial Consideration” hereunder with. For purposes of this definition, “fair market value” will be determined on a per share basis and will mean the average closing price of Clovis common stock for the ten (10) trading days immediately preceding the date such Sublicensee or Distributor agreement is executed, or, if there is no trading market for the security issued, the good faith determination of the board of directors of Clovis as to its fair market value (taking into account, inter alia, the pricing of other recent security issuances by Clovis).